Fresh off making its U.S. landfall, British CRO TranScrip Partners has expanded into Hong Kong, bringing its development and marketing services to Asia.
AMRI has signed a long-term contract with the U.K.'s defense department, agreeing to take an investigational drug to Phase I with a chance to re-up once there.
Counting on a boom in the Asian demand for injectables, contract manufacturer West Pharmaceutical Services has opened the doors on a nearly 40,000-square-foot facility.
Quintiles has kicked off a study to determine whether early genomic profiling of cancer patients can help inform physician decisions and match the right participant with the right study, a method the CRO said could speed up the development process of personalized drugs.
While drug developers have been outsourcing studies in China for years, the country's fast-growing local market has created a need for in-China, for-China services. That's why CRO giant Parexel has launched Dĭng Huī, a Beijing-headquartered offshoot dedicated to helping clients get their therapies on the Chinese market.
Canadian CRO JSS has bought LatAm Clinical Trials, a Colombian-headquartered provider of Phase I-IV services across the Andes.
CRO inVentiv Health has launched a crowdsourced physician network, signing up doctors interested in late-stage research to speed the recruitment process for trial sponsors.
Private equity giant KKR has finally a sealed a deal more than $1.3 billion in the making, closing its acquisitions of PRA and ReSearch Pharmaceutical Services to create what it says is the world's fourth-largest CRO.
Contract manufacturer Capsugel is pouring millions into three facilities around the world, looking to bolster its bandwidth in soft gelatin and liquid-fill hard capsules.
PPD is working to get therapeutic area experts into its highest offices, poaching UCB's former head of immunology to lead its efforts in the field.
Quintiles has finalized a deal for CRO Novella Clinical, snapping up its client base of emerging drug and device developers.
U.K. contract manufacturer Aesica is counting on a bullish market for solid dose diabetes drugs, and the company has poured $48 million into one of its plants to meet the demand.
Catalent has partnered up with Supernus Pharmaceuticals to supply the generics maker's extended-release epilepsy drug, a product the companies say has a chance to snag a share of a big market.
CRO inVentiv Health has struck up two deals to expand its offerings, launching a policy-focused joint venture and a partnership aimed at clinical trial site selection.
Indiana-headquartered CRO Harlan Laboratories has expanded its specialty research production facility in Southern Europe, offering contract breeding service for sponsors who need animal models for clinical trials.
In-transition drugmaker Columbia Laboratories is looking to cash in on the high-growth market for outsourced drug development, snatching up U.K. CRO Molecular Profiles for $25 million.
Theorem Clinical Research has struck a deal with Charles River Laboratories, adding the early-phase-focused CRO's capabilities to its drug development platform.
Bayer has again reached out to DKSH to expand its presence in Asia, this time tasking the Swiss company with helping it push its therapies in Singapore.
India's TCG Lifesciences has signed up to handle early phase work for Debiopharm's drug-resistant bacteria program, helping the Swiss drug developer as it chases a share of the antibiotics market.
Italian contract researcher CROS NT has landed in the U.S., snapping up medical device-focused CRO Stat-Tech.